Class information for: |
Basic class information |
| ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
|---|---|---|---|
| 29712 | 148 | 21.4 | 71% |
Classes in level above (level 2) |
| ID, lev. above |
Publications | Label for level above |
|---|---|---|
| 3562 | 947 | DOUBLE DATA ENTRY//RISK BASED MONITORING//SOURCE DATA VERIFICATION |
Terms with highest relevance score |
| Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|---|
| 1 | HOP ADULTES LA TIMONE | Address | 4 | 75% | 2% | 3 |
| 2 | OMES | Author keyword | 2 | 67% | 1% | 2 |
| 3 | INTEGROME | Author keyword | 1 | 50% | 1% | 2 |
| 4 | ESPACE ETH MEDITERRANEEN | Address | 1 | 27% | 2% | 3 |
| 5 | UMR ADES 7268 | Address | 1 | 17% | 3% | 4 |
| 6 | APOPTOSIS EFFECTOR GENES | Author keyword | 1 | 50% | 1% | 1 |
| 7 | BORRERIA HISPIDA | Author keyword | 1 | 50% | 1% | 1 |
| 8 | CEIPI | Address | 1 | 50% | 1% | 1 |
| 9 | CNRSESPACE ETH MEDITERRANEENHOP ADULTES TIMONE | Address | 1 | 50% | 1% | 1 |
| 10 | EFSCNRS | Address | 1 | 50% | 1% | 1 |
Web of Science journal categories |
Author Key Words |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
|---|---|---|---|---|---|---|---|
| 1 | OMES | 2 | 67% | 1% | 2 | Search OMES | Search OMES |
| 2 | INTEGROME | 1 | 50% | 1% | 2 | Search INTEGROME | Search INTEGROME |
| 3 | APOPTOSIS EFFECTOR GENES | 1 | 50% | 1% | 1 | Search APOPTOSIS+EFFECTOR+GENES | Search APOPTOSIS+EFFECTOR+GENES |
| 4 | BORRERIA HISPIDA | 1 | 50% | 1% | 1 | Search BORRERIA+HISPIDA | Search BORRERIA+HISPIDA |
| 5 | LIFE SPAN STUDIES | 0 | 33% | 1% | 1 | Search LIFE+SPAN+STUDIES | Search LIFE+SPAN+STUDIES |
| 6 | MOLECULAR TUMOR BOARD | 0 | 33% | 1% | 1 | Search MOLECULAR+TUMOR+BOARD | Search MOLECULAR+TUMOR+BOARD |
| 7 | REGULATORY APPROACHES | 0 | 33% | 1% | 1 | Search REGULATORY+APPROACHES | Search REGULATORY+APPROACHES |
| 8 | GOAL PROFILES | 0 | 25% | 1% | 1 | Search GOAL+PROFILES | Search GOAL+PROFILES |
| 9 | PROTEIN SMALL MOLECULE INTERACTION | 0 | 25% | 1% | 1 | Search PROTEIN+SMALL+MOLECULE+INTERACTION | Search PROTEIN+SMALL+MOLECULE+INTERACTION |
| 10 | SUSTAINED ACTIVATION | 0 | 11% | 1% | 1 | Search SUSTAINED+ACTIVATION | Search SUSTAINED+ACTIVATION |
Key Words Plus |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | METABOLITE INTERACTIONS | 1 | 50% | 1% | 1 |
| 2 | PERIODICITY DETECTION | 1 | 50% | 1% | 1 |
| 3 | TO CONSUMER GENOMICS | 1 | 50% | 1% | 1 |
| 4 | PROSTATE CANCER AGGRESSIVENESS | 0 | 25% | 1% | 1 |
| 5 | HUMAN POPULATION GROWTH | 0 | 14% | 1% | 1 |
| 6 | HYPERCHOLESTEROLEMIA 25 YEARS | 0 | 100% | 1% | 1 |
Journals |
Reviews |
| Title | Publ. year | Cit. | Active references |
% act. ref. to same field |
|---|---|---|---|---|
| Genomic chronicles Rare is frequent | 2012 | 0 | 9 | 56% |
| The future of Connected Health in preventive medicine | 2013 | 0 | 10 | 50% |
| Implementing Personalized Medicine in a Cancer Center | 2011 | 20 | 13 | 15% |
| HUMAN-GENOME-ANALYSIS - AN EXPERIMENT IN SCIENCE POLICY | 1992 | 0 | 10 | 70% |
| Personalized Cancer Medicine: Molecular Diagnostics, Predictive Biomarkers, and Drug Resistance | 2013 | 51 | 52 | 2% |
| Personalizing Oncology: Perspectives and Prospects | 2013 | 34 | 42 | 2% |
| iPOP Goes the World: Integrated Personalized Omics Profiling and the Road toward Improved Health Care | 2013 | 4 | 14 | 7% |
| Systematic investigation of protein-small molecule interactions | 2013 | 2 | 38 | 5% |
| Personalized medicine in oncology: tailoring the right drug to the right patient | 2010 | 14 | 72 | 1% |
| Predicting phenotypic variation from genotypes, phenotypes and a combination of the two | 2013 | 3 | 58 | 2% |
Address terms |
| Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | HOP ADULTES LA TIMONE | 4 | 75% | 2.0% | 3 |
| 2 | ESPACE ETH MEDITERRANEEN | 1 | 27% | 2.0% | 3 |
| 3 | UMR ADES 7268 | 1 | 17% | 2.7% | 4 |
| 4 | CEIPI | 1 | 50% | 0.7% | 1 |
| 5 | CNRSESPACE ETH MEDITERRANEENHOP ADULTES TIMONE | 1 | 50% | 0.7% | 1 |
| 6 | EFSCNRS | 1 | 50% | 0.7% | 1 |
| 7 | MOFFITT | 1 | 50% | 0.7% | 1 |
| 8 | MRC CAN CONT | 1 | 50% | 0.7% | 1 |
| 9 | PHARMACOGEN WORKING PARTY | 1 | 50% | 0.7% | 1 |
| 10 | SECUR MED | 1 | 50% | 0.7% | 1 |
Related classes at same level (level 1) |
| Rank | Relatedness score | Related classes |
|---|---|---|
| 1 | 0.0000170078 | INTERNATIONAL CLINICAL RESEARCH//ACTUAL BENEFIT//CHILD ABUSE HOMICIDE |
| 2 | 0.0000091025 | GENE PATENTS//INTELLECTUAL PROPERTY RIGHTS//EUROPEAN PATENT CONVENTION |
| 3 | 0.0000077621 | PATENTING DYNAMICS//RESEARCH ORGANISATIONS//BIOTECH FIRMS |
| 4 | 0.0000070734 | INTERACTION CONDITION//TARGETED CLINICAL TRIALS//INFLUENCE CONDITION |
| 5 | 0.0000063225 | EVOLUT CANC//PETOS PARADOX//TRANSLAT CANC THER EUT |
| 6 | 0.0000060776 | SCIENCES SOCIALES ET SANTE//UMR CNRS 5118//DIRECT REG RHONE ALPES |
| 7 | 0.0000060143 | GENOME ASSEMBLY//VARIANT CALLING//TARGET ENRICHMENT |
| 8 | 0.0000058027 | PATENTING ANALYSIS//THERAPEUTIC INDUSTRY//AGROBIOTECHNOLOGY |
| 9 | 0.0000055753 | DIRECT TO CONSUMER//PUBLIC HEALTH GENOMICS//DIRECT TO CONSUMER GENETIC TESTING |
| 10 | 0.0000054542 | PHARMACOGENOMICS//PERSONALIZED MEDICINE//PROGRAM PERSONALIZED MED TARGETED THER EUT |